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Abstract: Evaluation of costs and benefits associated with cancer screening should include
consideration of any psychological and behavioral impact associated with screening participation.
Research examining the psychological and behavioral impact of screening asymptomatic women for
ovarian cancer (OC) was considered. Research has focused upon potential negative psychological (e.g.,
distress) and behavioral (e.g., reduced future screening participation) impact of false positive (FP) OC
test results. Results suggest FP OC screening results are associated with greater short-term OC-specific
distress. While distress dissipates over time it may remain elevated relative to pre-screening levels
for several weeks or months even after clinical follow-up has ruled out malignancy. The likelihood of
participation in future OC screening may also be reduced. Research focused upon identification of
any beneficial impact of participation in OC screening associated with receipt of “normal” results was
also considered. This research suggests that a “normal” screening test result can have psychological
benefits, including increased positive affect and beliefs in the efficacy of screening. It is concluded
that any psychological or behavioral harms attributable to OC screening are generally very modest in
severity and duration and might be counterbalanced by psychological benefits accruing to women
who participate in routine OC screening and receive normal test results.
Keywords: ovarian cancer; psychological; psychosocial; behavioral; screening; false positive
test result
1. Introduction
For some cancers, participation in cancer screening can lead to early diagnosis and an associated
improvement in five-year survival. Consequently, great effort has been expended to develop
cost-effective screening tests and protocols for cancers of the breast, colon, rectum, cervix, prostate,
lung, and ovary—cancers with a high likelihood of treatment success when diagnosed and treated
at an early stage of disease. Furthermore, for those screening tests for which the evidence suggests
cost-effectiveness, great effort has been expended to ensure widespread uptake and appropriate repeat
screening by screening-eligible individuals.
While participation in cancer screening can improve prognosis for some cancers, cancer screening
is not without its drawbacks. All cancer screening approaches yield some proportion of inconclusive
or abnormal results. These results typically require additional clinical follow-up to determine if a
malignancy is present. Clinical follow-up might include surgery or biopsy, performance of a second-line
screening test, or perhaps simply a repeat of the original screening test. In most instances, follow-up
indicates the original abnormal or inconclusive screening test result is benign—no malignancy is
present. Such false positive (FP) results may not be psychologically or behaviorally benign, however.
A survey of recipients of FP test results in the context of breast, prostate, cervical or colorectal
cancer screening found 40% described the experience as “very scary” or “the scariest time of my
life” [1]. In general, research has shown a FP cancer screening test result can negatively impact
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both psychological (e.g., distress) and behavioral (e.g., participation in future cancer screening)
outcomes [2–6], although research suggesting no impact is also available (e.g., [7]).
Recommendation of any cancer screening test for routine use in asymptomatic, average-risk
women is based on the relative balance of the benefits and costs associated with that screening test.
Identification of the benefits of any cancer screening test is relatively straightforward. Whether a cancer
screening test results in a significant reduction in the number of deaths due to that specific cancer
(i.e., cancer-specific mortality) is the primary determinant of the benefits of a particular screening test.
A broader view of the benefits of a screening test could include consideration of any psychological or
behavioral benefits associated with a screening test. Though rarely considered, participation in cancer
screening may yield positive outcomes including reductions in cancer worry or increases in feelings of
reassurance and well-being [8,9].
As one might expect, calculation of the costs of a screening test include consideration of the
monetary costs associated with testing. In addition, calculation of the costs of a screening test should
also include the “costs” associated with FP screening test results. These costs include the monetary as
well as physical morbidity costs associated with performance of additional follow-up procedures or
unnecessary surgeries. In addition, a FP screening test result might also exact certain psychological
or behavioral costs. Psychological costs include fear or anxiety, a heightened sense of personal risk
for cancer, or reduced confidence in the efficacy of the screening test, all of which might result in a
significant behavioral cost—a lessened likelihood of returning for repeat screening in the future. If the
collective costs associated with a screening test exceed the collective benefits of screening, one might
well conclude that a particular screening test does more harm than good.
The purpose of this paper is to consider the literature regarding the psychological and behavioral
impact of participation in routine screening for ovarian cancer (OC). Evidence regarding the potential
for OC screening to yield both positive and negative psychological and behavioral outcomes will
be considered.
2. Screening for Ovarian Cancer
When diagnosed and treated at a localized stage, OC is associated with a good prognosis.
The five-year relative survival rate is 92% [10]. Unfortunately, the majority of cases of OC (61%)
are diagnosed with late stage disease where existing treatment approaches are less likely to be
successful and five-year relative survival rates are correspondingly only 27% [10]. Given this state
of affairs, considerable effort has been expended to develop cost-effective approaches to screening
for OC [11–16]. For the most part, these approaches include transvaginal ultrasonography (TVS) and
serum tests for cancer antigen 125 (CA125), alone or in combination. While demonstrating some
value in promoting early detection of OC in average-risk, asymptomatic women, no approach to OC
screening has been shown to significantly reduce OC-specific mortality in asymptomatic, average-risk
women in a prospective, randomized trial. As a result, implementation of routine screening for
OC in asymptomatic, average-risk women has been controversial. Currently, the US Preventive
Services Task Force recommends against routine screening for OC in asymptomatic, average-risk
women (D recommendation) [17]. However, despite this recommendation, screening for OC is widely
available and utilized for asymptomatic women at either average or elevated risk for OC. A recent
survey of primary care physicians and obstetrician-gynecologists in the USA found many (33%)
believed TVS and CA125 were effective screening tests for OC and many would offer OC screening
tests to low (28%) and medium risk (65%) women [18].
3. Impact of False Positive OC Screening Test Results
Similar to screening tests for other cancers, screening for OC yields a certain proportion of
inconclusive or abnormal test results [19]. For asymptomatic women at average risk for OC,
approximately 5%–10% of OC screening tests yield an inconclusive or abnormal result, necessitating
clinical follow-up. Fortunately, the vast majority of inconclusive or abnormal OC screening test results
Diagnostics 2017, 7, 15 3 of 11
are ultimately deemed benign. While clinically benign, however, a FP OC screening test result may
not be psychologically or behaviorally benign. An inconclusive or abnormal OC test result requiring
additional clinical follow-up could understandably cause a woman to consider the possibility of a
diagnosis of OC, resulting in a heightened sense of personal vulnerability. This in turn could result in
the experience of fear, anxiety, and/or distress as well as a reduced likelihood of returning for future
OC screening.
What is the evidence for such reactions? To answer this question a group of 10 studies are
considered [20–29]. While an attempt was made to use PubMed to identify all relevant studies,
a systematic review of the literature was not conducted and consequently no guarantee is made
regarding the completeness of the studies considered here. Each of the 10 studies considered involves
comparison of two groups of women participating in OC screening: women receiving a “normal”
screening test result (i.e., Normal group) and women receiving an abnormal test result with clinical
follow-up revealing no malignancy present (i.e., FP group). Comparison of these two groups of women
has the potential to shed light on the impact of a FP OC screening test result. The specific OC screening
test(s) employed varies across these studies but each employed CA125 testing or ultrasonography,
typically transvaginal sonography (TVS), either alone or in combination. The psychological and
behavioral outcomes the Normal and FP groups are compared upon vary widely across studies.
The most common outcomes being generic mental health outcomes (e.g., state anxiety, depression,
distress), OC-specific measures of distress and worry, OC risk perception, and participation in future
cancer screening, either actual or stated intention to participate. These studies also vary widely with
regard to study design (e.g., cross sectional vs. longitudinal), sample size in both the Normal and FP
groups, and the timing of the assessment of outcomes (e.g., short-term vs long-term). Finally, some of
these studies focused upon OC screening for women at intermediate or high risk for OC, typically due
to a strong family history of OC [23,25–28]. The remaining studies focused upon OC screening among
asymptomatic women generally at average risk for OC [20–22,24,29].
3.1. Impact of FP Results on Women at Intermediate or High Risk for OC
In an early study, 266 women at risk for familial OC underwent either transabdominal or
transvaginal ultrasonagraphy with color Doppler imaging [27]. Women with abnormal results on
initial scan returned in six weeks for a repeat scan. Women with repeat abnormal results at the repeat
scan were referred for surgery. All women completed a questionnaire 6–15 weeks before the initial scan
and again after their initial scan. Women also completed the same questionnaire after a repeat scan.
Psychological outcomes assessed included OC risk perception, cancer worry, coping style, depression
and anxiety symptoms, and general distress. Results indicated that following an initial scan, before
a repeat scan ruled out the presence of malignancy, women receiving an abnormal result (n = 51)
reported greater cancer worry, general distress, and anxiety than women receiving a normal scan result
(i.e., Normal group; n = 189). Of women receiving an abnormal result at the initial scan, 32 received a
normal result at the repeat scan and thus constituted a FP group. In the FP group, distress returned
to baseline levels but remained elevated relative to the Normal group. Overall, it was concluded FP
results are associated with increased distress in the short-term but this adverse impact is neither severe
nor persistent.
Participants in this initial study completed the same study questionnaire as in the initial study
one year after their initial scan [28]. In general, one year after their initial scan, women in the FP
group did not differ from women in the Normal group with regard to distress and anxiety. However,
more women in the FP group described themselves as “more worried” about cancer than women
in the Normal group. It was concluded while FP results may be associated with some increased
worry about cancer in the longer term, there is little evidence to suggest severe and persistent adverse
psychological effects.
Kauff et al. examined women at intermediate risk for OC due to a personal or family history
of breast and/or ovarian cancer but no documented BRCA1/2 mutation [25]. Women were offered
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semi-annual OC screening using TVS, CA125 testing, and pelvic examination. Women completed
a baseline assessment at enrollment in the screening program and follow-up assessments every six
months thereafter in conjunction with OC screening. Impact on mental quality of life (QOL) was
indexed by the Mental Component Score of the Medical Outcome Study Short Form-36. At least one
follow-up assessment was completed by 135 women. During a mean of 19.8 months of follow-up,
52 women experienced ≥1 abnormal OC screening test result. None of these women were ultimately
deemed to have OC and constituted the FP group. Women in the FP group evidenced a clinically and
statistically significant mean 6.4 point decrease in their Mental Component Score between baseline and
their most recent follow-up assessment. (Lower scores represent poorer mental QOL). Women with no
abnormal OC screening test result constituted the Normal group (n = 83) and evidenced a statistically
and clinically insignificant mean 0.67 point drop in their Mental Component Score. It was concluded
for women at intermediate risk for OC, FP screening results are associated with a significant decline in
mental QOL.
As part of the United Kingdom Familial Ovarian Cancer Screening Study (OKFOCSS), women at
increased genetic risk for OC (estimated lifetime risk >10%) participated in an OC screening program
involving thrice yearly CA125 testing coupled with annual TVS [23]. If an abnormal test result
occurred for either type of testing, women were recalled for retesting within two months. Women
(n = 1999) completed a baseline assessment (T1) one month prior to an initial CA125 test and a
follow-up assessment one week after receiving the result of this initial test (T2). Women receiving
an abnormal test result at any time completed an additional follow-up one week after repeat of the
screening test ruled out malignancy and they were returned to routine screening (T3). These women
constituted the FP group (n = 167). The remaining women who received only normal test results during
participation in the screening program constituted the Normal group. Finally, all women completed a
final follow-up assessment nine months after receiving a normal test result (n = 825) or nine months
after return to routine screening after receiving a FP result (n = 87) (T4). Specific outcomes assessed at
each assessment included OC-specific distress, anxiety and depression symptoms, and reassurance.
Compared to the Normal group the FP group reported moderately elevated OC-specific distress one
week after being notified of their abnormal result. No difference in OC-specific distress was evident
at T3 or T4, after women with FP results returned to routine screening. No differences with regard
to anxiety, depression, or reassurance were noted between the Normal screening and FP groups at
any assessment point. Finally, women in the FP group were significantly more likely to withdraw
from the screening program (primarily for risk-reducing salpingo oophorectomy) (OR = 4.38). It was
concluded FP screening results are associated with transient OC-specific distress but are not associated
with sustained psychological harm.
Finally, 111 female BRCA1/2 mutation carriers who had not undergone risk-reducing surgery
(i.e., salpingo oophorectomy) participated in a screening program involving both annual breast cancer
screening and OC screening involving both CA125 testing and TVS [26]. All abnormal screening
test results were followed by additional imaging and biopsy when appropriate. All participants
completed a questionnaire prior to a baseline screening visit, as well as 3 and 12 months post-baseline.
Psychological outcomes assessed included general anxiety, perceived absolute and comparative risk
for OC, and OC worry. Women receiving normal OC screening test results following baseline screening
constituted the Normal group and those receiving abnormal results with no cancer subsequently
detected constituted a FP group. No significant differences were found between the Normal and FP
groups for any of the OC risk or worry outcomes at either the 3 or 12 month follow-ups. Furthermore,
there were no differences between the two groups in the likelihood of undergoing risk-reducing
surgery. It was concluded FP test results were not associated with large increases in risk perception,
cancer worry, or uptake of risk-reducing surgery. Unfortunately, only two women received abnormal
CA125 test results (<2% of the sample) while the number of women receiving FP TVS test results was
not reported. As a result, it is unclear whether the lack of significant findings might be due to a true
absence of effect or simply due to inadequate statistical power.
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3.2. Summary: Impact of FP Results on Women at Intermediate or High Risk for OC
Each of the studies considered in this group examined the impact of a FP screening test result
on one or more psychological outcomes. Overall, the evidence suggests that a FP result in screening
programs targeted at women at intermediate or high risk for OC is associated with significantly poorer
psychological status in the immediate aftermath of an abnormal OC screening test result. This appears
particularly true with regard to cancer-specific worry and distress [23,25,27]. Little evidence suggests
much impact on more general indices of depression, anxiety or mental health or on perceptions
of OC risk. Any impact on psychological status appears to be short-lived, however, as differences
between FP and Normal groups generally decline over time following determination no malignancy is
present [23,28]. The study by Kauff et al. [25] appears to be an exception to this general conclusion,
however, as they found FP results were associated with significant and long-term declines in a generic
measure of mental health. However, their data analytic strategy did not account for when a FP result
was experienced in the course of the mean nearly 20 months of observation. This makes it difficult to
attribute any observed declines in mental health status to the experience of a FP screening test result.
Finally, Brain et al. found women receiving FP results were over four times more likely to withdraw
from their OC screening program [23]. Withdrawal was typically followed by risk-reducing surgery,
however, eliminating the need for further OC screening. It was unclear, however, whether women
in the FP group were more likely than women in the Normal group to discontinue participation in
OC screening in the absence of risk-reducing surgery. This is a critical missing piece of information
given any risk-reducing impact of a screening program is predicated upon continued, appropriate
participation with the program [30].
3.3. Impact of FP Results on Women at Average Risk for OC
The studies considered here examined the psychological and behavioral impact of a FP OC
screening test result on asymptomatic women generally at average risk for OC [20–22,24,29]. Andersen
et al. examined women (n = 592) at “conventional” risk for OC (i.e., ≤1 first degree relative with OC)
undergoing alternating CA125 and TVS testing every six months for 18 months [20]. Abnormal CA125
results were followed by TVS screening while abnormal TVS results required repeat TVS screening in
six to eight weeks. Measures of QOL, worry about OC risk, and OC-specific distress were completed
at a baseline assessment prior to the initial OC screening test and a follow-up two years post-baseline,
after the screening program was concluded. At follow-up, women receiving a FP OC screening test
result at some point during the two-year screening period (n = 32) were compared to similar women
who received normal screening test results (i.e., Normal group). The FP group reported significantly
greater worry about OC risk. Cancer-specific distress and quality of life did not differ between the FP
and Normal screening groups. It was concluded FP screening test results may have long-term effects
and increase worry about cancer risk.
Barrett et al. examined the psychological impact of a FP screening test in women participating in
the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), a randomized trial
of annual multimodal OC screening [21]. Women (n = 202,638) were randomized to one of three arms:
(1) OC screening with CA125 testing followed, if necessary, by TVS (CA125+TVS) as a second line test;
(2) OC screening with TVS; or (3) no OC screening. Following receipt of an abnormal screening test
result women in the CA125+TVS arm underwent a repeat CA125 test with (Level 2) or without (Level 1)
TVS testing. Women in the TVS group underwent a repeat TVS test by a senior ultrasonographer
within three months (Level 1) or a repeat TVS test or biopsy within six weeks (Level 2). All women
completed a baseline questionnaire prior to randomization. Women in the two screening groups who
received an abnormal screening test result (n = 22,035) completed a questionnaire following each
abnormal screen and annually thereafter. The questionnaire included measures of state anxiety as
well as general psychological morbidity as assessed by the General Health Questionnaire (GHQ-12).
Results indicated greater psychological morbidity in women after receipt of a FP test result but only
for women receiving more intensive repeat screening (i.e., Level 2 repeat screening). In other words,
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women in the CA125+TVS screening group exhibited greater psychological morbidity only if repeat
screening involved repeat of both the CA125 and TVS tests while women in the TVS screening group
exhibited greater psychological morbidity only if repeat screening involved a TVS scan or biopsy (i.e.,
Level 2 repeat screening). No differences between the FP and Normal groups were found for state
anxiety. It was concluded a FP test results in slightly increased psychological morbidity when an
abnormal screening test result is followed by more intensive forms of repeat screening.
The remaining studies in this group examined asymptomatic, average-risk women participating
in an ongoing trial of OC screening using annual TVS at the University of Kentucky [22,24,29]. In this
trial, an abnormal TVS test result requires repeat of the TVS screening test in 2–16 weeks. In an initial
study [22], women (n = 540) completed a baseline assessment immediately before undergoing a routine
annual TVS screening test and follow-up assessments two weeks and four months post-baseline.
A single-item measure of OC risk perception (i.e., perceived lifetime personal risk) as well as measures
of general and OC-specific distress were completed at all assessments. Women receiving a FP screening
test result (n = 33) at baseline were compared to women receiving a normal screening test result
(i.e., Normal group; n = 507). Compared to women receiving a “normal” TVS test result, women
receiving a FP result reported significantly elevated OC-specific distress at the two-week follow-up,
before a repeat TVS test had clarified whether a malignancy was present. Distress returned to baseline
levels at four-month follow-up, after repeat of the TVS test indicated no malignancy was present.
No differences between the FP and Normal groups on mood disturbance, depression, or OC risk
perception were found. It was concluded a FP test result is associated with a significant, but transient,
increase in OC-specific distress.
As a follow-up to this initial study, a larger longitudinal study examining psychological and
behavioral responses to receipt of a FP OC screening test result was implemented [29]. Women
receiving a FP TVS test result (n = 375) in the course of routine, annual TVS screening were compared
to women (n = 375) receiving a normal test result (i.e., Normal group). Women in the FP group
were matched with women in the Normal group with regard to age, family history of OC, and OC
screening history (prior FP result, number of prior TVS tests). Women in the FP group completed
a baseline assessment immediately prior to undergoing a repeat TVS test, required to clarify the
nature of a recent abnormal TVS test 2 to 16 weeks earlier. Women in the Normal group completed a
baseline assessment immediately prior to a routine, annual TVS screening test. Both groups completed
follow-up assessments one and four months after baseline. Results indicated FP test results were
associated with clinically significant increases in OC-specific distress with distress remaining elevated
through the four month follow-up. Women receiving a FP result also reported significantly higher
perceptions of OC risk on two different, two-item composite measures of risk (Personal OC Risk and
Comparative OC Risk) and fewer perceived positive consequences of screening participation. A FP test
result also impacted screening intentions as the FP group reported at one month follow-up significantly
weaker intentions to return for future OC screening. No differences between the FP and Normal groups
were found with regard to depressive symptoms, benefit finding, or beliefs in the effectiveness of OC
screening at any of the study assessments. It was concluded FP results negatively impact both affective
(OC-specific distress) and cognitive (risk perception) outcomes in both the short and intermediate
term. The negative psychological impact of a FP test is still evident for several months after repeat
testing has ruled out malignancy and may serve to reduce motivation to participate in future routine
OC screening.
Finally, Floyd et al. examined the impact of a FP test result on women’s interest in receiving
health-related information [24]. Based on the possibility a FP screening test result could be experienced
as a very scary and threatening event [1], it was hypothesized a FP result may serve as a “teachable
moment” [31] and enhance interest in obtaining additional information about OC as well as other
health-related topics. A Normal screening group (n = 124) consisted of women undergoing a routine,
annual TVS test with receipt of normal results. This group completed a baseline assessment prior
to undergoing routine TVS screening. A FP screening group (n = 279) consisted of women who had
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received an abnormal TVS test result 2–16 weeks earlier and were returning for a repeat TVS test to
clarify whether a malignancy was present. These women completed a baseline assessment prior to
undergoing this repeat TVS screening test. All women completed a follow-up assessment one month
post-baseline where interest in receiving information about 10 different health- and cancer-related
topics was assessed. Contrary to hypothesis, results indicated women receiving FP screening test results
were significantly less interested in receiving health- and cancer-related information than women
receiving normal screening results. It was concluded receipt of a FP result does not represent a teachable
moment when women may be more receptive to health information and health behavior change.
Rather receipt of a FP screening test result appears to make women less interested in health-related
information, including information regarding OC.
3.4. Summary: Impact of FP Results on Women at Average Risk for OC
Most studies in this group examined the impact of a FP screening test result on one or more
psychological outcomes [20–22,29]. In each of these studies, a negative impact on psychological
outcomes was observed. Receipt of a FP result was associated with poorer psychological status,
particularly OC-specific worry [20] and OC-specific distress [22,29]. Little evidence suggests FP results
exert a significant impact on more general measures of psychological morbidity or distress, although
one study did find elevated psychological morbidity in women receiving a FP result requiring more
intense, invasive repeat testing after an abnormal result [21]. While it is clear FP results impact
OC-specific distress, the duration of this impact is not completely clear. It is quite apparent receipt of
an abnormal screening test result is associated with an immediate and pronounced spike in OC-specific
distress [22,29] which remains elevated for at least several weeks or months even after repeat OC
screening rules out malignancy [29]. Overall, the evidence suggests that receipt of a FP screening test
result increases OC-specific distress and worry in the short term and quite possibly in the intermediate
term. As for other outcomes, the data are sparse or mixed. The two studies that examined the impact
of a FP test result on perceptions of OC risk yielded mixed results [22,29]. While one study found no
impact upon OC risk perception [22], a larger and better designed study found a FP result resulted in
higher perceptions of OC risk up to four months after repeat TVS testing ruled out malignancy [29].
The failure to find a significant impact on OC risk perception in the earlier study [22] could be due to a
lack of statistical power as well as use of a relatively crude measure of OC risk perception. The earlier
study [22] included only 33 women in the FP result group compared to 375 women in the later
study [29], making it less likely a “true” impact on OC risk perception could be detected in the earlier
study. Additionally, the earlier study indexed OC risk perception using only a single, single-item
measure of risk perception. In contrast, the later study [29] found significant effects on two separate,
two-item composite measures of OC risk perception. Finally, a FP result may impact the likelihood
of participation in future screening as receipt of a FP result was associated with significantly weaker
intentions to return for future OC screening [29].
4. Impact of Normal OC Screening Test Results
As might be expected, an abnormal or FP test result appears to have at least some negative
impact on psychological and behavioral outcomes. Might the opposite be true? Does receipt of a
“normal” OC screening test result yield a positive impact on psychological or behavioral outcomes?
In contrast to the attention focused upon the impact of abnormal or FP results, it appears the impact of
a “normal” test result on psychological and behavioral outcomes has received less attention. In an
initial study, high-risk women (n = 275) underwent ultrasound screening for OC [32]. Nearly 34
reported feeling reassured after screening. In a more recent and comprehensive study, asymptomatic,
average-risk women (n = 560) completed a baseline assessment immediately prior to undergoing
routine, annual TVS screening for OC as well as follow-up assessment two weeks and four months
post-baseline [33]. All women received a “normal” screening test result. Growth curve modeling
revealed receipt of a “normal” test result was associated with a significant decrease in OC-specific
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distress and significant increases in positive affect, belief in the efficacy of OC screening, and knowledge
of OC risk factors between the baseline and four-month follow-up assessment. No effect was observed
on OC risk perceptions, negative affect, or more generic measures of distress (i.e., depression, mood
disturbance). It was concluded participation in routine OC screening with receipt of a normal result can
positively impact affective and cognitive psychological outcomes that can serve to promote continued
participation in OC screening.
5. Summary and Recommendations
Determination of the value of any cancer screening test requires careful consideration of the
costs and benefits associated with that screening test. Obviously, certain types of costs and benefits
are weighed more heavily than others. The paramount benefit of a screening test is the extent to
which it reduces cancer-related mortality. On the cost side of the ledger, the economic and physical
morbidity costs (e.g., surgeries) associated with a screening test are weighed most heavily. Less
frequently considered are any psychological and behavioral costs and benefits associated with a cancer
screening test.
The purpose of this paper was to consider the psychological and behavioral impact, both costs
and benefits, associated with participation in OC screening. The studies we considered are diverse
in methodology and design. Most of these studies focused upon documenting the psychological
“costs” associated with abnormal, ultimately FP, OC screening test results. In general, these studies
clearly suggest that women who experience a FP OC screening test result report more OC-specific
worry and distress in the short-term [22,23,27,29]. This is unsurprising, of course, given receipt
of an abnormal result raises at least the possibility of a subsequent diagnosis of OC. This distress
appears to dissipate over time, but may still be present to a degree four months to a year or more
after receipt of an abnormal result and after clinical follow-up has ruled out a malignancy [20,28,29].
This general conclusion appears to be true regardless of the OC risk status of the asymptomatic women
being screened.
In contrast to the findings for OC-specific distress and worry, the impact of a FP screening test
result on other psychological outcomes is less clear. The impact on generic measures of mental health,
depression and anxiety is mixed with some research showing a negative impact [21,25,27] and other
research showing no impact [20,22,23,29]. Similarly, the impact of a FP result on perceptions of OC risk
is also mixed with some studies finding no impact [22,27] but another, larger, better-designed study
finding increased perceptions of OC risk in women experiencing a FP result [29].
With regard to behavioral costs associated with a FP OC screening test result, FP test results may
be associated with reduced future participation in OC screening [23] or reduced intentions to return
for routine screening in the future [29]. Given the effectiveness of any cancer screening modality is
predicated upon continued screening uptake at appropriate intervals, this is a significant potential cost
associated with FP results in the OC screening setting.
In contrast to the negative impact of a FF OC screening test result, it appears woman may
benefit from participation in routine OC screening when a “normal” screening test result is received.
For asymptomatic, average-risk women, participation in OC screening with receipt of a “normal” test
result was associated with a significant decrease in OC-specific distress and significant increases in
positive affect, belief in the efficacy of OC screening, and knowledge of OC risk factors over a four
month period following screening [33]. Additionally, comparison of women receiving FP and normal
results found women receiving normal screening test results attributed more positive consequences
to their screening experience such as greater feelings of well-being and reassurance [29]. This data is
provocative in its suggestion that participation in screening may not be a completely benign experience
from a psychological and behavioral standpoint. Rather, participation in screening may create affective
and cognitive conditions that may not only be inherently positive and reinforcing, but may also serve
to further promote continued participation in OC screening.
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While showing some ability to detect OC at an earlier stage, randomized trials have failed to
show a reduction in cancer-specific mortality in asymptomatic, average-risk women participating in
OC screening programs. Coupled with consideration of the monetary costs of OC screening and the
potential physical morbidity costs (e.g., surgery) associated with FP test results, the US Preventive
Services Task Force recommends against routine screening for OC in asymptomatic, average-risk
women (D recommendation) [17]. Despite this negative recommendation, routine screening of
asymptomatic women at average risk for OC is unlikely to go away. OC screening is well accepted
by many physicians [18] as well as by the public. An overwhelming majority of women participating
in the University of Kentucky OC screening program indicated they agreed or strongly agreed that
TVS screening is effective in the early diagnosis of OC [29]. As a result, further research on the
psychological and behavioral impact of participation in OC screening is warranted. While more
research is needed, what is particularly needed is better research. Future research examining the
impact of FP screening test results should be characterized by (1) sufficient numbers of women
receiving abnormal or FP results to ensure adequate statistical power and the ability to interpret null
findings; (2) longitudinal assessment to enable identification of the duration of impact of a specific
abnormal or FP test result on key psychological and behavioral outcomes; and (3) removal of women
who undergo risk-reducing oophorectomy from analyses focused upon understanding the impact of
FP results on future screening participation.
In addition, there is likely benefit from expanding the focus of research regarding the psychological
and behavioral impact of participation in OC screening. In particular, more research is needed
regarding the potential impact of participation in routine OC screening with receipt of a “normal”
test result. While research has examined the potential positive impact of a normal test result [33] the
potential negative impact of a normal test result has received scant, if any, attention. Potential negative
impact might involve delay in help-seeking following any subsequent onset of symptoms related to OC
or a general complacency about health. Two other areas are also largely unexamined: the psychological
and behavioral impact of false negative OC screening test results—receipt of a normal screening test
result when OC is present—and the impact of true positive OC screening test results. In the latter case,
the psychological and behavioral impact of a diagnosis of OC may differ depending on whether OC
was screening- or symptomatically-detected.
In conclusion, the research considered here does not suggest that FP test results in the course of
screening asymptomatic women for OC result in significant, durable psychological harm. In addition,
there is some suggestion that participation in routine screening for OC may confer psychological
benefits. Some have contended OC screening “does more harm than good” [34]. If true, this contention
is true based largely on consideration of the physical harms associated with surgeries performed
for diagnostic or preventive purposes following abnormal OC screening results. Any psychological
or behavioral harms attributable to OC screening appear to be, at worst, rather modest in severity
and duration and might well be counterbalanced by psychological benefits accruing to women who
participate in routine OC screening and who receive normal test results.
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